I am an adult hematologist currently appointed as Assistant Professor in the Division of Hematology, Department of Medicine, and cross appointed to the Department of Oncology. I obtained a Master's of Science in Medical Genetics at the University of Alberta (2003), followed by a Medical Degree at the University of Saskatchewan (2006), residency training at the University of Alberta (Internal Medicine 2006-2009) and the University of Calgary (Hematology 2009-2011), and a fellowship in lymphoma at the University of Calgary (2011-2012). My clinical and research interests centre around lymphoproliferative malignancies in adults.
I conduct clinical and collaborative biomedical research in lymphoproliferative disease. I have developed a registry for Alberta patients diagnosed with post-transplant lymphoproliferative disorder (PTLD) following solid organ transplant and am working on several clinical research projects utilizing this resource, including collaborative work with other major transplant centres in Canada. My most recent research grant investigates a rapid novel technique for predicting results of FISH, a molecular test currently used to identify high risk patients with diffuse large B cell lymphoma, as a means to expedite patient care and save public health care dollars. I am also an investigator in several interventional clinical trials conducted at the Cross Cancer Institute and the University of Alberta Hospital for patients with non-Hodgkin and Hodgkin lymphoma, chronic lymphocytic leukemia, and cold agglutinin disease.
University Hospital Foundation Medical Research Competition 2017
Title: “Novel MYC Immunohistochemistry Classifier to Predict MYC Translocation by Fluorescence In Situ Hybridization in Diffuse Large B Cell Lymphoma”
Role: Principal Investigator
Total Budget: CAN$: 35,000
Alberta Innovates Health Solutions (AIHS) Collaborative Research and Innovation Opportunities (CRIO) Project – Cancer 201301 Competition
Title: “Improving the Prevention, Diagnosis, and Treatment of Post-
Transplant Lymphoproliferative Disorders after Solid Organ Transplantation
Using Peripheral Blood and Tissue Biomarkers”
Role: Collaborative Co-Lead
Total Budget: CAN$: 737,363
biomarker, chronic lymphocytic leukemia, clinical trials, diffuse large B cell lymphoma, Epstein-Barr virus, follicular lymphoma, immunosuppression, lymphoma, Post-transplant lymphoproliferative disorder, prognostic factors, Solid organ transplant
Journal Articles (since 2010):
- Chung, R.*, Peters, A.C.*, Armanious, H., Anand, M., Gelebart, P., Lai, R. (*equal contributors). Biological and clinical significance of GSK-3beta in mantle cell lymphoma: an immunohistochemical study. Int. J. Clin. Exp. Pathol., 2010; 3:244-53.
- Peters, A.C., Duan, Q., Russell, J.A., Duggan, P., Owen, C., Stewart, D.A. Event-free survival following autologous stem-cell transplantation for relapsed or refractory follicular lymphoma is commonly durable, and is associated with recent rituximab exposure and low risk FLIPI score. Leuk. Lymphoma, 2011; 52:2124-9.
- Lam, G.Y., Halloran, B.P., Peters, A.C., Fedorak, R.N. Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. World J. Gastrointest. Pathophysiol. 2015; 6:181-192.
- Oh, D.H., Li, H., Duan, Q., Villa, D., Peters, A., Chua, N., Owen, C.J., Connors, J.M., Stewart, J.A. Quantifying benefit of autologous transplantation for relapsed follicular lymphoma patients via instrumental variable analysis. Biol. Blood Marrow Transplant. 2016 May;22(5):941-8
- Saini, L., Brandwein, J., Turner, R., Larratt, L., Hamilton, M., Peters, A., Wu, C.M., Zhu, N., Patterson, J.M., Bolster, L., Mant, M., Ritchie, B., Liew, E., Ghosh, S., Sandhu, I. The FLAG Chemotherapy Regimen Is an Alternative to Anthracycline Based Therapy for the Treatment of Acute Myeloid Leukemia for Patients with Preexisting Cardiac Disease. Eur. J. Haematol. 2016 Mar. 29 [Epub ahead of print]
- Saini, L., Brandwein, J., Turner, R., Larratt, L., Hamilton, M., Peters, A., Wu, C.M., Zhu, N., Taparia, M., Patterson, J.M., Bolster, L., Mant, M., Ritchie, B., Liew, E., Mirza, I., Quest, G., Nahirniak, S., Ghosh, S., Sandhu, I. Incremental value of the bone marrow trephine biopsy in detecting residual leukemia following treatment for Acute Myeloid Leukemia. Leuk. Res. 2016 Apr. 8; 45:47-52.
- Peters, A., Olateju, T., Deschenes, J., Shankarnarayan, S.H., Chua, N., Shapiro, A.M., Senior, P. Post-transplant lymphoproliferative disorder following clinical islet transplantation: report of the first two cases. Am J Transplant 2017 Sep;17(9):2474-80.
- Peters, A., Segun, M., Cervera, C., Mabilangan, C., Ghosh, S., Lai, R., Iafolla, M., Doucette, K., Preiksaitis, J. The Changing Epidemiology of Post-Transplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single Centre Experience. Transplantation, 2018 Feb. 26 [Epub ahead of print]
- Preiksaitis, J.K., Cockfield, S., Peters, A.C. Epstein-Barr Virus Infection and Lymphoproliferative Disorders after Transplantation. In: Ljungman, P., Snydman, D., Boeckh, D., editors. Transplant Infections, Fourth Edition. Switzerland: Springer International; 2016
Published Abstracts (since 2010)
- Peters, A.C., Owen, C.J., Doucette, K., Preiksaitis, J., Lymphopenia and EBER-negativity predict poor survival in patients with post-transplant lymphoproliferative disorder (PTLD) treated in the rituximab era, ASH Annual Meeting, San Diego, CA, 2011. Blood, Nov. 2011; 118: Abstract 1645
- Stubbins, R.J., Peters, A.C., Mabilangan, C., Owen, C.J., Mansoor, A., Lai, R., Preiksaitis, J.K., Morphologic Evolution in Post-Transplant Lymphoproliferative Disorders (PTLD): A Clinicopathologic Series. Blood, Dec. 2015; 126(23): Abstract 5008
- Stubbins, R.J., Zhu, J., Lai, R., Owen, C.J., Preiksaitis, J., Peters, A.C. CD3 T-Cell Infilltrates at Diagnosis Predicts Overall Survival in Solid Organ Transplant Recipients with Post-Transplant Lymphoproliferative Disorders (PTLD). Blood 2016; 128:1873
- Assouline, S., Amrein, L., Banerji, V., Caplan, S., Owen, C. J., Hasegawa, W., Robinson, S., Shavikumar, S., Prica, A., Peters, A., Hagerman, L., Rodriguez, L., Skamene, T., Panasci, L., Chen, B. E., & Hay, A. E. (2017). A Phase II Clinical Trial of the Pan PI3K Inhibitor, Buparlisib, for the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia: Canadian Cancer Trials Group IND.216. Blood, 130(Suppl 1), 4319.
- Davies, G., Ghosh, S., Oh, D., Manna, M., Peters, A., Stewart, C., & Stewart, D. A. (2017). Significant Adverse Consequences of Initial Watchful Waiting for Follicular Lymphoma Patients: A Retrospective Analysis of Patients Diagnosed in Alberta from 1994-2011. Blood, 130(Suppl 1), 4041.
- Manna, M., Lee-Ying, R., Davies, G., Peters, A., Oh, D., Stewart, C., & Stewart, D. A. (2017). Autologous Transplantation Improves Survival Rates for Follicular Lymphoma Patients Who Relapse within 2-Years of Chemoimmunotherapy: A Multi-Centre Retrospective Analysis of Consecutively Treated Patients in the Real World. Blood, 130(Suppl 1), 3298.
- Rojas Vasquez, M., Desai, S. J., Peters, A., Urschel, S., Yap, J., Lai, R., Morgan, C., & Preiksaitis, J. (2017). Monomorphic Post Transplant Lymphoproliferative Disorder (Diffuse Large B Cell Lymphoma subtype) Successfully Treated without Chemotherapy after Solid Organ Transplant in Children. Blood, 130(Suppl 1), 1579.
My clinical interests closely align with my research interests. I am a local and regional expert inpost-transplant lymphoproliferative disorders (PTLD) after solid organ transplant having treated most adult PTLD patients in Edmonton since 2012 and having developed provincial guidelines for clinical management. I also treat patients with most lymphoid malignancies, including chronic lymphocytic leukemia, Hodgkin and non-Hodgkin lymphoma, and hairy cell leukemia at the Cross Cancer Institute and the University of Alberta Hospital.